TLDR
- VRAX spikes as UK trials and U.S. plans push clinical progress forward.
- Virax Biolabs jumps on early trial wins and bold 2026 strategy.
- VRAX gains big as Long COVID studies hit key milestones early.
- Clinical momentum fuels strong breakout for Virax Biolabs stock.
- VRAX soars on trial success, U.S. expansion, and immune tech growth.
Virax Biolabs Group Limited (VRAX) stock climbed nearly 60% during early trading, briefly nearing the $0.80–$0.90 range.
Virax Biolabs Group Limited, VRAX
This sharp rise came after the company revealed its 2026 strategy and detailed key clinical milestones. The stock later stabilized at $0.63 as market enthusiasm settled.
VRAX Highlights Completion of UK Trials and Clinical Progress
VRAX confirmed the early completion of recruitment for its first UK study, VRX-002, involving 160 participants. This study evaluates the ViraxImmune T cell diagnostic for post-acute infection syndromes like Long COVID, ME/CFS, and PTLD. According to the company, initial data from this trial will be available in the second quarter of 2026.
The company has already initiated and fully enrolled a second UK study, VRX-003, led by Eurofins. Both trials aim to strengthen its submission to the UK’s MHRA for regulatory approval. This progress marks a shift from planning to active execution across its core immunology programs.
VRAX presented new clinical data at the World Immune Regulation Meeting in Davos. The findings indicated immune system dysfunction in PAIS patients, which aligns with the intended use of ViraxImmune™. These developments enhance the company’s scientific credibility and reinforce the diagnostic’s clinical relevance.
U.S. Collaboration and Regulatory Pathway Advance
In the United States, VRAX signed a research agreement with Emory University to launch a clinical trial focused on long COVID. The company aims to use this trial to support its U.S. regulatory strategy for ViraxImmune™. Emory’s ADJUST Center and ELIAD will lead the research under this collaboration.
The company held a formal Q-sub meeting with the U.S. FDA in 2025 to clarify regulatory expectations. Feedback from that meeting is being integrated into its upcoming clinical design. The U.S. trial is scheduled to begin in 2026 and is expected to support future commercial efforts.
This transatlantic development supports the global expansion of the ViraxImmune™ platform. With both UK and U.S. progress underway, the company solidifies its regulatory and clinical footprint. VRAX sees this as vital to reaching commercial viability in PAIS diagnostics.
Revenue Potential from RUO Products and Financial Stability
VRAX continues to develop its ImmuneSelect RUO (research-use-only) product line for immune profiling. These products are already in use by labs and researchers studying chronic immune dysfunction and related diseases. As RUO tools, they can generate revenue without diagnostic approval, offering a quicker commercial path.
The company considers ImmuneSelect both a revenue driver and a promotional channel for ViraxImmune™. As usage increases, awareness and credibility of the ViraxImmune platform could rise across global research institutions. This strategy aligns with the company’s goal to create a sustainable diagnostic ecosystem.
VRAX maintains a debt-free balance sheet and reports having enough cash to execute short-term priorities. This financial stability supports continued product development and regulatory submissions. As a result, the company is well-positioned to pursue both clinical and commercial success in 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
